

Shionogi Announces Corporate Reorganization and Personnel Reassignment

OSAKA, Japan, September 22, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi will implement the following corporate reorganization and personnel reassignment as of October 1, 2022.

1. Corporate Reorganization (see attached organization chart)

New establishment of the Academia Collaboration Office

The Academia Collaboration Office will be newly established within the Integrated Disease Care Division to strive to resolve issues affecting society in various fields through the integration of know-how concerning industry-academia collaboration, and the further promotion of partnerships involving Shionogi's internal value chain and academia, in the infectious disease, psychoneurological diseases and pain.

2. Personnel Reassignments (Effective; October 1, 2022)

New Position	Name	Present Position
Healthcare Business Supervisory Unit		
Senior Director, Integrated Disease Care Division Academia Collaboration Office	Hiroyuki Yoshida	Integrated Disease Care Division

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html

SHIONOGI Divisions (October 1, 2022)

		Corporate Executive Meeting	
The Annual General Meeting of Shareholders	Board of Directors Chief Executive Officer and Representative Director		
	Chief Executive Officer and Representative Director	Compliance Committee	
Board of A	uditors		
R&D Supervisory Unit	Research Division	Laboratory for Drug Discovery and Disease Research	
		Laboratory for Medicinal Chemistry Research	
		Laboratory for Drug Discovery and Development	
		API R&D Laboratory	
		Formulation R&D Laboratory Intellectual Property Department	
	Drug Development and Regulatory Science Division	Project Management Department	
		Clinical Research Department	
		Medical Science Department	
		Regulatory Affairs Department	
		Pharmacovigilance Department	
			Biostatistics Center
	Biopharmaceutical Research Division	Laboratory for Bio-Drug Discovery	
		Laboratory for Bio-Modality Research	
		Analysis and Evaluation Laboratory	
L		Business Development Department	
		Investment Strategy Department	
Healthcare Business Supervisory Unit	Pharmaceutical Commercial Division	Promotion Department - Region 1	
Treatcitcate busilless Supervisory Offic	Filamaceutical Commercial Division	Promotion Department - Region 2	
		Promotion Department - Region 3	
		Promotion Department - Region 4	
		Promotion Department - Region 5	
		Distribution Management Department	
			Sales Promotion Office
			Specialty Product Office
-	Integrated Disease Care Division	New Product Planning Department	
	integrated biocase care binsion	Medical Affairs Department	Drug Information Center
		Corporate Social Responsibility Department	Office for Children's Bright Future
			Office for Stewardship to Proper Use of Medicine
		New Business Promotion Department	
			Academia Collaboration Office
		Government Affairs Department	
		Vaccine and Diagnostic Drug Department	Diagnostic Drug Office
			Partnership Promotion Office
		Tokyo Branch Office	· · · ·
Cumply Cupon isony Unit	Clobal Ruciness Division	Clobal Rusiness Department	
Supply Supervisory Unit	Global Business Division	Global Business Department Global Supply Chain Strategy Department	
		Global Supply chain Strategy Department	
Corporate Supervisory Unit	Corporate Strategy Division	Corporate Planning Department	
		Finance & Accounting Department	
		Corporate Communications Department	
		Corporate Secretariat	
	Administration Division	Human Resources Department	Human Capital Strategy Office
	Administration bidsion		Career Development Office
		Value Chain Support Department	R&D Support Office
			R&D Support Office Healthcare Business Support Office
		General Administration Department	
		General Administration Department Legal Affairs Department	
		General Administration Department	
	DX Promotion Division	General Administration Department Legal Affairs Department Sustainability Management Department	
-	DX Promotion Division	General Administration Department Legal Affairs Department Sustainability Management Department IT & Digital Solution Department	
-		General Administration Department Legal Affairs Department Sustainability Management Department IT & Digital Solution Department Data Science Department	
-	Corporate Quality Assurance and Ethics & Compliance Management Division	General Administration Department Legal Affairs Department Sustainability Management Department IT & Digital Solution Department	Healthcare Business Support Office
-		General Administration Department Legal Affairs Department Sustainability Management Department IT & Digital Solution Department Data Science Department	